Efficacy, Safety, and Steroid Sparing Effect of Acthar in Patients With Hematologic Manifestations of Systemic Lupus Erythematosus

Trial Profile

Efficacy, Safety, and Steroid Sparing Effect of Acthar in Patients With Hematologic Manifestations of Systemic Lupus Erythematosus

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Corticotropin (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Nov 2017 Planned End Date changed from 1 May 2018 to 1 Dec 2018.
    • 24 Nov 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.
    • 07 Dec 2016 Planned End Date changed from 1 May 2017 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top